No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention

American Heart Journal

Volumn 145, Issue 1, 2003, Pages 42-46

  Resnic, Frederic S ^a   Wainstein, Marco ^a   Lee, Michael K Y ^a   Behrendt, Dominik ^a   Wainstein, Rodrigo V ^a   Ohno Machado, Lucila ^a   Kirshenbaum, James M ^a   Rogers, Campbell D K ^a   Popma, Jeffrey J ^a   Piana, Robert ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE; NITROPRUSSIDE SODIUM; VERAPAMIL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD FLOW VELOCITY; CARDIOGENIC SHOCK; CONTROLLED STUDY; DEATH; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SAPHENOUS VEIN GRAFT; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0037217716     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.36     Document Type: Article

References (9)

1. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 1994;89:2514-8.
2. Vallejo E, Pena-Duque MA, Norono O, et al. The no-reflow phenomenon: Its incidence and clinical characteristics in a series of cases. Arch Inst Cardiol Mex 1998;68:247-52.
3. Fugit D, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol 2000;12:80-5.
4. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996;93:879-88.
5. Mak KH, Challapalli R, Eisenberg MJ, et al. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. Epic Investigators. Am J Cardiol 1997;80:985-8.
6. Assali AR, Sdringola S, Ghani M, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of "no-reflow" phenomenon. Catheter Cardiovasc Interven 2000;51:27-31.
7. Fischell TA, Carter AJ, Foster MT, et al. Reversal of "no-reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998;45:360-5.
8. Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: Initial human clinical experience. J Am Coll Cardiol 2001;37:1335-43.
9. Baim DS. 30 Day results of the SAFER study. Presented at: Proceedings of the Transcatheter Therapeutics Annual Scientific Sessions; November 18, 2000; Washington, DC.